Daiwa Securities Group Inc. Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Daiwa Securities Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1,508.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 11,759 shares of the company’s stock after acquiring an additional 11,028 shares during the period. Daiwa Securities Group Inc.’s holdings in Recursion Pharmaceuticals were worth $116,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Recursion Pharmaceuticals by 116.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after acquiring an additional 2,817 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Recursion Pharmaceuticals by 25.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock valued at $77,000 after buying an additional 2,050 shares during the last quarter. Private Advisor Group LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $79,000. Plancorp LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $82,000. Finally, QRG Capital Management Inc. purchased a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $86,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 3.6 %

Shares of NASDAQ:RXRX opened at $8.12 on Friday. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.54 and a 12-month high of $16.75. The company has a market capitalization of $1.91 billion, a PE ratio of -5.24 and a beta of 0.76. The business has a 50 day moving average of $10.37 and a two-hundred day moving average of $9.13.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen began coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $12.75.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total transaction of $106,457.10. Following the completion of the transaction, the director now directly owns 7,312,917 shares of the company’s stock, valued at approximately $68,010,128.10. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CFO Michael Secora sold 23,124 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total transaction of $175,279.92. Following the completion of the transaction, the chief financial officer now directly owns 1,231,055 shares of the company’s stock, valued at approximately $9,331,396.90. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total value of $106,457.10. Following the transaction, the director now directly owns 7,312,917 shares of the company’s stock, valued at $68,010,128.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 348,218 shares of company stock valued at $3,536,464. 19.96% of the stock is owned by company insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.